Vyne Therapeutics Inc (VYNE) - Net Assets
Based on the latest financial reports, Vyne Therapeutics Inc (VYNE) has net assets worth $27.77 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($30.16 Million) and total liabilities ($2.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Vyne Therapeutics Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $27.77 Million |
| % of Total Assets | 92.06% |
| Annual Growth Rate | N/A |
| 5-Year Change | -42.91% |
| 10-Year Change | N/A |
| Growth Volatility | 79.6 |
Vyne Therapeutics Inc - Net Assets Trend (2015–2025)
This chart illustrates how Vyne Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of Vyne Therapeutics Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Vyne Therapeutics Inc (2015–2025)
The table below shows the annual net assets of Vyne Therapeutics Inc from 2015 to 2025. For live valuation and market cap data, see VYNE company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $27.77 Million | -46.69% |
| 2024-12-31 | $52.09 Million | -41.30% |
| 2023-12-31 | $88.73 Million | +184.39% |
| 2022-12-31 | $31.20 Million | -35.85% |
| 2021-12-31 | $48.64 Million | +29.72% |
| 2020-12-31 | $37.49 Million | -45.27% |
| 2019-12-31 | $68.51 Million | -47.45% |
| 2018-12-31 | $130.38 Million | +328.60% |
| 2017-12-31 | $-57.03 Million | -93.72% |
| 2016-12-31 | $-29.44 Million | -84.55% |
| 2015-12-31 | $-15.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vyne Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 74160600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.00K | 0.01% |
| Other Comprehensive Income | $2.00K | 0.01% |
| Other Components | $785.41 Million | 2828.79% |
| Total Equity | $27.77 Million | 100.00% |
Vyne Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Vyne Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Transtouch Technology
TWO:3623
|
$21.06 Million |
|
Przedsiebiorstwo Przemyslu Spozywczego PEPEES S.A.
WAR:PPS
|
$21.07 Million |
|
Sphere 3D Corp
NASDAQ:ANY
|
$21.08 Million |
|
Kip Mcgrath Education Centres Ltd
AU:KME
|
$21.08 Million |
|
Philippos Nakas S.A
AT:NAKAS
|
$21.05 Million |
|
Sogn Sparebank
OL:SOGN
|
$21.05 Million |
|
Citigold Corporation Limited
F:CHP
|
$21.04 Million |
|
Jervois Global Ltd
AU:JRV
|
$21.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vyne Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 52,086,000 to 27,765,000, a change of -24,321,000 (-46.7%).
- Net loss of 26,483,000 reduced equity.
- Other comprehensive income decreased equity by 18,000.
- Other factors increased equity by 2,180,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-26.48 Million | -95.38% |
| Other Comprehensive Income | $-18.00K | -0.06% |
| Other Changes | $2.18 Million | +7.85% |
| Total Change | $- | -46.69% |
Book Value vs Market Value Analysis
This analysis compares Vyne Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.97x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $-99.54 | $0.63 | x |
| 2016-12-31 | $-97.30 | $0.63 | x |
| 2017-12-31 | $-199.39 | $0.63 | x |
| 2018-12-31 | $433.21 | $0.63 | x |
| 2019-12-31 | $145.33 | $0.63 | x |
| 2020-12-31 | $20.82 | $0.63 | x |
| 2021-12-31 | $17.01 | $0.63 | x |
| 2022-12-31 | $9.79 | $0.63 | x |
| 2023-12-31 | $8.64 | $0.63 | x |
| 2024-12-31 | $1.22 | $0.63 | x |
| 2025-12-31 | $0.65 | $0.63 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vyne Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -95.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4646.14%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.09x
- Recent ROE (-95.38%) is above the historical average (-113.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.01 Million |
| 2016 | 0.00% | -2087.24% | 0.02x | 0.00x | $-11.12 Million |
| 2017 | 0.00% | -634.57% | 0.07x | 0.00x | $-23.37 Million |
| 2018 | -39.46% | -483.51% | 0.08x | 1.07x | $-64.48 Million |
| 2019 | -102.86% | -4026.51% | 0.02x | 1.16x | $-77.31 Million |
| 2020 | -681.64% | -1217.40% | 0.22x | 2.50x | $-259.32 Million |
| 2021 | -150.77% | -7876.37% | 0.01x | 1.38x | $-78.19 Million |
| 2022 | -74.39% | -4865.83% | 0.01x | 1.31x | $-26.33 Million |
| 2023 | -32.06% | -6710.38% | 0.00x | 1.10x | $-37.33 Million |
| 2024 | -76.48% | -7950.90% | 0.01x | 1.28x | $-45.04 Million |
| 2025 | -95.38% | -4646.14% | 0.02x | 1.09x | $-29.26 Million |
Industry Comparison
This section compares Vyne Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vyne Therapeutics Inc (VYNE) | $27.77 Million | 0.00% | 0.09x | $21.05 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Vyne Therapeutics Inc
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pa… Read more